Induction of potent anti-tumor immunity by direct injection of Ad-LIGHT at the site of tumor inoculation

Cytotherapy

Volumn 9, Issue 4, 2007, Pages 386-396

  Zhang, J ^a,b   Wang, Q ^b   Zhao, D ^b   Cao, X ^b,c  

^a SHAOXING UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Adenovirus vector; Gene therapy; LIGHT TNFSF14; Melanoma

Indexed keywords

ADENOVIRUS VECTOR; GAMMA INTERFERON; HERPESVIRUS ENTRY MEDIATOR LIGAND; INTERLEUKIN 2; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; C57BL 6 MOUSE; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; IN VIVO STUDY; MELANOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR IMMUNITY; VIRAL GENE THERAPY; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNITY; INFLAMMATION; INJECTIONS; KILLER CELLS, NATURAL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEUTROPHIL INFILTRATION; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; TRANSDUCTION, GENETIC; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 14;

EID: 34347206362     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1080/14653240701326749     Document Type: Article

References (29)

1. Rigel, DS and Carucci, JA. (2000) Malignant melanoma: Prevention, early detection, and treatment in the 21st century. CA Cancer J Clin, 50, pp. 215-236.
2. Chada, S., Ramesh, R. and Mhashilkar, AM. (2003) Cytokine- and chemokine-based gene therapy for cancer. Curr Opin Mol Ther, 5, pp. 463-474.
3. Luster, AD and Leder, P. (1993) IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo. J Exp Med, 178, pp. 1057-1065.
4. Hellstrom, KE, Newby, SA and Chen, L. (1996) Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors. J Exp Med, 183, pp. 639-644.
5. Ahmad, M., Rees, RC and Ali, SA. (2004) Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother, 53, pp. 844-854.
6. Foss, FM. (2002) Immunologic mechanisms of antitumor activity. Semin Oncol, 29, pp. 5-11.
7. Mauri, DN, Ebner, R. and Montgomery, RI (1998) LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity, 8, pp. 21-30.
8. Tamada, K., Shimozaki, K. and Chapoval, AI (2000) LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J Immunol, 164, pp. 4105-4110.
9. Granger, SW and Rickert, S. (2003) LIGHT-HVEM signaling and the regulation of T cell-mediated immunity. Cytokine Growth Factor Rev, 14, pp. 289-296.
10. Zhai, Y., Guo, R. and Hsu, TL (1998) LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J Clin Invest, 102, pp. 1142-1151.
11. Harrop, JA, Reddy, M. and Dede, K. (1998) Antibodies to TR2 (herpesvirus entry mediator), a new member of the TNF receptor superfamily, block T cell proliferation, expression of activation markers, and production of cytokines. J Immunol, 161, pp. 1786-1794.
12. Tamada, K., Shimozaki, K. and Chapoval, AI (2000) Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nat Med, 6, pp. 283-289.
13. Lee, Y. and Liu, W. (2004) Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol, 5, pp. 141-149.
14. Lotze, MT and Papamichail, M. (2004) A primer on cancer immunology and immunotherapy. Cancer Immunol Immunother, 53, pp. 135-138.
15. Sprinzl, GM, Kacani, L. and Schrott-Fischer, A. (2001) Dendritic cell vaccines for cancer therapy. Cancer Treat Rev, 27, pp. 247-255.
16. Wang, Q. and Ju, DW (2001) Intratumoral IL-18 gene transfer improves therapeutic efficacy of antibody-targeted superantigen in established murine melanoma. Gene Ther, 8, pp. 542-550.
17. Peter, I., Nawrath, M. and Kamarashev, J. (2002) Immunotherapy for murine K1735 melanoma: Combinatorial use of recombinant adenovirus expressing CD40L and other immunomodulators. Cancer Gene Ther, 9, pp. 597-605.
18. Lasek, W., Mackiewicz, A. and Czajka, A. (2000) Antitumor effects of the combination therapy with TNF-alpha gene-modified tumor cells and interleukin 12 in a melanoma model in mice. Cancer Gene Ther, 7, pp. 1581-1590.
19. Tanaka, M., Saijo, Y. and Sato, G. (2000) Induction of antitumor immunity by combined immunogene therapy using IL-2 and IL-12 in low antigenic Lewis lung carcinoma. Cancer Gene Ther, 7, pp. 1481-1490.
20. Ruehlmann, JM, Xiang, R. and Niethammer, AG (2001) MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma. Cancer Res, 61, pp. 8498-8503.
21. Ware, CF. (2003) The TNF superfamily. Cytokine Growth Factor Rev, 14, pp. 181-184.
22. Gaur, U. and Aggarwal, BB. (2003) Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol, 66, pp. 1403-1408.
23. Locksley, RM, Killeen, N. and Lenardo, MJ. (2001) The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell, 104, pp. 487-501.
24. + T-cell immunity to reject established tumors. Blood, 107, pp. 1342-1351.
25. Hisada, M., Yoshimoto, T. and Kamiya, S. (2004) Synergistic antitumor effect by coexpression of chemokine CCL21/SLC and costimulatory molecule LIGHT. Cancer Gene Ther, 11, pp. 280-288.
26. Benihoud, K., Yeh, P. and Perricaudet, M. (1999) Adenovirus vectors for gene delivery. Curr Opin Biotechnol, 10, pp. 440-447.
27. Whiteside, TL and Herberman, RB. (1995) The role of natural killer cells in immune surveillance of cancer. Curr Opin Immunol, 7, pp. 704-710.
28. Mosmann, TR and Sad, S. (1996) The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today, 17, pp. 138-146.
29. Nishimura, T., Iwakabe, K. and Sekimoto, M. (1999) Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med, 190, pp. 617-627.